LSTM Home > LSTM Research > LSTM Online Archive

The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial

Downloads

Downloads per month over past year

Khawaja, Muhammed, Wang, Duolao ORCID: https://orcid.org/0000-0003-2788-2464, Pocock, Stuart, Redwood, Simon and Thomas, Martyn (2014) 'The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial'. Trials, Vol 15, e300.

[img]
Preview
Text
Trials_15_300.pdf - Published Version
Available under License Creative Commons Attribution.

Download (492kB)

Abstract

Background

Current guidelines recommend treatment of significant coronary artery disease by concomitant coronary artery bypass grafting (CABG) in patients undergoing surgical aortic valve replacement. However there is no consensus as to how best to treat coronary disease in high-risk patients requiring transcatheter aortic valve implantation (TAVI).

Methods/Design

The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial is a randomized, controlled open-label trial of 310 patients randomized to treatment of significant coronary artery disease by percutaneous coronary intervention (PCI - test arm) or no PCI (control arm). Significant coronary disease is defined as ≥1 lesion of ≥70% severity in a major epicardial vessel or 50% in a vein graft or protected left main stem lesion. The trial tests the hypothesis that the strategy of performing pre-TAVI PCI is non-inferior to not treating such coronary stenoses with PCI prior to TAVI, with a composite primary outcome of 12-month mortality and rehospitalization. Secondary outcomes include efficacy end-points such as 30-day mortality, safety endpoints including bleeding, burden of symptoms, and quality of life (assessed using the Seattle Angina Questionnaire and the Kansas City Cardiomyopathy Questionnaire).

In conclusion, we hope that using a definition of coronary artery disease severity closer to that used in everyday practice by interventional cardiologists - rather than the 50% severity used in surgical guidelines - will provide robust evidence to direct guidelines regarding TAVI therapy and improve its safety and efficacy profile of this developing technique.

Trial registration

ISRCTN75836930, http://www.controlled-trials.com/ISRCTN75836930 (registered 19 November 2011).

Item Type: Article
Additional Information: The electronic version of this article is the complete one and can be found online at: http://www.trialsjournal.com/content/15/1/300
Subjects: WG Cardiovascular System > WG 20 Research (General)
WG Cardiovascular System > Heart. Heart Diseases > WG 200 General works
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI): https://doi.org/10.1186/1745-6215-15-300
Depositing User: Lynn Roberts-Maloney
Date Deposited: 31 Mar 2015 08:56
Last Modified: 06 Sep 2019 15:26
URI: https://archive.lstmed.ac.uk/id/eprint/5049

Statistics

View details

Actions (login required)

Edit Item Edit Item